ArdorComm Media Group

Monday, July 7, 2025 1:31 PM

Health & Wellness Community

Doctors on alert for monkey pox symptoms at Delhi airport

Monkeypox symptoms would immediately get passengers at Delhi’s IGI airport directed to Lok Nayak hospital, according to officials aware of the situation on Monday. The decision was arrived at during a review meeting that Lieutenant Governor VK Saxena presided over. Inspecting passengers for high fevers, joint, and back pain, the airport health team’s doctors would reportedly refer suspected patients to LNJP. The National Institute of Virology in Pune will receive samples from patients who are hospitalised to the hospital. Additional district magistrate Vikram Singhal stated that the district administration would place suspected patients’ families under quarantine and conduct contact tracing. After the review meeting, the LG tweeted: “Reviewed the monkeypox situation in Delhi along with CS, secretary health, DGHS and others concerned. Was apprised of preparedness in terms of medical services, hospital infrastructure, tracing, testing, surveillance and clinical management. Advised officials to ensure all preventive measures. I appeal to the people to not panic and follow all prescribed prevention and treatment protocols.” One case of monkeypox has been reported in Delhi so far; the victim is a 34-year-old Paschim Vihar resident who has never travelled overseas. 13 contacts that belonged to his family or the doctors who initially treated him and suggested home quarantine have been tracked down by the district administration. The health teams presently have the capability to test just those with suspected Covid symptoms, according to officials positioned at the airport. According to sources, 2-3% of international passengers on each flight landing at IGI airport are randomly tested. “Some of the symptoms in both Covid and monkeypox are the same. After randomly testing passengers for Covid-19, we let them go to their destination. If found positive, the reports are sent to them as well as the district and state authorities. It is important that we increase surveillance to screen passengers for the symptoms of monkeypox. We have already written to the government for the same,” an official said, asking to remain anonymous. A team of 150 health professionals are currently stationed at Delhi Airport to screen travellers for Covid-19. A decision to increase the number of doctors, testing teams, and health professionals at the airport has not yet been made, according to sources.

Doctors on alert for monkey pox symptoms at Delhi airport Read More »

NTAGI panel reviews data for Corbevax as booster for adults who got Covishield, Covaxin shots

According to official sources, the National Technical Advisory Group on Immunization’s Covid working group has examined the data of Biological E’s Corbevax to allow it as a booster for those aged 18 and over completely vaccinated with Covishield or Covaxin. The NTAGI panel did not yet make a recommendation at their meeting on Wednesday. On June 4, the Drugs Controller General of India (DCGI) approved Corbevax as a precautionary dose for individuals 18 years of age and above. Corbevax, India’s first locally produced RBD protein subunit vaccine, is currently being administered to children between the ages of 12 and 14. According to an official source who spoke to the media agency, “The NTAGI panel reviewed the data of Biological E’s Corbevax as a booster for those aged 18 and above fully vaccinated with either Covishield or Covaxin,” In accordance with a 75-day special drive that started on July 15, everyone aged 18 and over is receiving free precautionary doses of the Covid vaccine at government immunisation centres. As part of the government’s Azadi Ka Amrit Mahotsav to commemorate the 75th anniversary of India’s Independence, the “COVID Vaccination Amrit Mahotsava” programme is being undertaken with the intention of increasing the adoption of Covid precaution dosages. To date, the nation has administered more than 6 crore precautionary doses.

NTAGI panel reviews data for Corbevax as booster for adults who got Covishield, Covaxin shots Read More »

India registers 20,557 new COVID19 cases, bringing the total number of active cases to 1,45,654

India’s COVID-19 immunisation coverage has surpassed 200.61 crore (92.71 crore second dose and 6.11 crore precaution dosage have been provided so far under National Vaccination Drive). There have been 26,04,797 doses given over the past 24 hours. The COVID-19 vaccine’s initial dosage has been given to more than 3.81 crore adolescents so far. 2,64,58,875 sessions have been used to accomplish this. In the past 24 hours, 18,517 patients have recovered, bringing the total number of recovered patients to 4,31,32,140. India now has a recovery rate of 98.47 percent. In the previous 24 hours, 20,557 new cases were reported. The number of active cases in India is presently 1,45,654. Currently, 0.33 percent of all positive cases in the nation are active cases. In the past 24 hours, 4,98,034 COVID-19 tests have been performed. In total, India has performed about 87.06 billion tests to date. Currently, the country’s weekly positivity rate is 4.64 percent, and its daily positivity rate is 4.13 percent.

India registers 20,557 new COVID19 cases, bringing the total number of active cases to 1,45,654 Read More »

Free Covid precaution doses will create healthier country: PM Modi

According to Prime Minister Narendra Modi, the government’s decision to provide free precaution doses of the Covid-19 vaccine to all adults over the age of 18 will increase immunisation rates in India and lead to a healthier nation. All citizens over the age of 18 will receive free precaution doses of the Covid-19 vaccine as part of the “Azadi Ka Amrit Mahotsav” celebrations beginning on July 15 and lasting for 75 days, according to Union minister Anurag Thakur, who announced the initiative after the Union Cabinet approved it earlier in the day on Wednesday. Modi stated in a tweet, “Vaccination is an effective means to fight COVID-19. Today’s Cabinet decision will further India’s vaccination coverage and create a healthier nation.” According to an official source, less than 1% of the target population of 77.10 crore people between the ages of 18 and 59 have received the precautionary dose so far. On April 10, India started vaccinating all adults over the age of 18 with a precautionary dose of the Covid-19 vaccine.

Free Covid precaution doses will create healthier country: PM Modi Read More »

Moderna to advance two Omicron vaccine candidates against newer variants

Moderna Inc. announced on Monday that it was moving forward with two Omicron vaccine candidates for the fall, one of which was created to protect against the BA.1 variant and the other to protect against the BA.4 and BA.5. Updated vaccines are being developed by vaccine producers like Moderna and rival Pfizer Inc. to combat the quickly spreading Omicron subvariants BA.4 and BA.5, which have recently expanded to the United States. Moderna claimed that a variety of market preferences for jabs against the subvariants informed its choice to develop the bivalent vaccines. The older 2020 variant and the more recent Omicron variants of the coronavirus are the two separate coronavirus variants that are targeted by bivalent vaccines. New clinical data for Moderna’s BA.1 variant-targeting mRNA-1273.214 vaccination revealed noticeably greater neutralising antibody responses against the fast-spreading BA.4 and BA.5 compared with the currently permitted booster, the firm says. The second booster candidate being researched by the company, mRNA 1273.222, is based on the BA.4/5 strain and is being created in compliance with current guidance from the U.S. Food and Drug Administration. Although the company’s BA.1 subvariant-targeting booster has improved durability and antibody response, according to Jefferies analyst Michael Yee, the original Omicron variant has already moved in the United States, and the FDA is likely to approve future BA.4/5 boosters. Source: Reuters

Moderna to advance two Omicron vaccine candidates against newer variants Read More »

Nairobi fly infection scare in North Bengal after Sikkim

The Darjeeling district administration has issued a warning on insect prevention after the acid fly or Nairobi fly infection has caused fear in a number of North Bengali communities. The insect primarily infects children and people with delicate skin. According to officials, the virus originally surfaced in Sikkim and has since spread. The virus has currently infected over 100 students at North Bengal University (NBU), Siliguri. Numerous students have left their hostels in a state of such anxiety and panic to return home. “We have issued an advisory on preventive measures such as wearing full sleeves, avoiding going outside in the evening, using mosquito nets, and using dim light inside houses,” said Darjeeling District Magistrate S Ponnambalam. Infected individuals should seek medical attention right away. According to the director of the Darjeeling District Hospital, the issue is merely a skin disease. In Darjeeling, there are now 3–4 cases, but none of them necessitate hospitalisation. People need to be cool and not panic because nothing seriously threatening would occur in this situation. In actuality, we are unsure whether the three to four patients who arrived coincidentally suffered an insect bite. I will however request a thorough explanation from my seniors. The District Magistrate declared, “Our goal right now is to control the infection and trace the breeding places. I request people not to panic.”

Nairobi fly infection scare in North Bengal after Sikkim Read More »

64% of Indians are confident after receiving two doses of the COVID-19 vaccine, not interested in precautionary dose: Survey

Mumbai: YouGov’s latest survey illustrates the attitudes of urban Indians on the COVID-19 booster dose amid new emerging variants and the fear of a potential fourth wave of the virus. Although 85% of urban Indians have received the COVID-19 vaccine, 11% are still waiting for their second dosage, and 5% have not received the vaccine and do not want to in the future. A higher proportion (74%) of people who have received the vaccine in both doses demonstrate an unwavering desire to get the booster dose. One in ten people are still doubtful about their choice, and nearly one in five (18%) are reluctant to take another shot. In comparison to tier I cities, tier II-III cities appear to have a higher rate of vaccine reluctance. Perhaps the rising number of cases in major cities and towns is prompting people in Tier 1 cities to protect themselves with an additional dose of the vaccine. Many people who have received the vaccination in its two doses are inclined to take the booster dose, but when we look at those who do not, the majority of respondents (64%) say that their faith in the vaccine in its two doses is the main reason they do not want to take a precautionary dose. Nearly one in five (19%) reported being afraid of the immediate adverse effects, such as fever, while 17% expressed concern about the supposed long-term side effects of the vaccines (like heart attacks, medical complications, etc). 15% of people have doubts about the booster dose’s efficacy, while 13% admitted they took the first dose of Covid against their will (due to travel or other obligations). Through the Har Ghar Dastak 2.0 campaign, which launched earlier last month, the Indian government has already administered more than 198.09 (1,98,09,87,178) crore vaccinations against COVID-19. It has also been actively working to improve vaccine coverage among the elderly. However, many people have not yet received the second dose of the vaccination or have not yet received a booster shot. In response to a question about whether the government should enforce booster dosages due to the rising number of cases, 76% of respondents said yes. Those who said they would without thinking twice take the booster dose demonstrated greater support (90 per cent).

64% of Indians are confident after receiving two doses of the COVID-19 vaccine, not interested in precautionary dose: Survey Read More »

Government asks states and UTs to observe Doctors Day in a variety of creative ways

ardorcomm-media

The Center has provided states and UTs with ideas for how to observe National Doctors Day on Friday, including having senior students visit local hospitals and taking photographs with medical professionals to post on social media. The Ministry of Health’s Directorate General of Health Services (DGHS) suggested celebrating “Ek Shaam Doctor Ke Naam” by holding cultural events that highlight the role of doctors in medical colleges, state government and district hospitals, community health centres, and at all health and wellness centres in a communication to the states and Union territories (UTs). “A social media campaign “Ek Selfie Doctor Ke Saath” can be initiated to encourage officials/general public to take selfies with their doctors and post them on their social media handles, popularizing through the hashtag #ThankYouDoctors,” DGHS Dr Atul Goel said. All practising doctors over the age of 75 are eligible for an award, and the event must be held in each block under the direction of the block administration. “Schools can arrange senior school student visits to local hospitals, providing students with the opportunity to interact with local doctors,” he said. Similar to this, it is possible to arrange for local hospital doctors to pay visits to local schools, orphanages, and nursing homes in order to encourage COVID-appropriate behaviour, healthy living, and awareness of the work done by the doctors. Source: PTI

Government asks states and UTs to observe Doctors Day in a variety of creative ways Read More »

Bajaj Allianz launches product to provide global health insurance coverage

Bajaj Allianz General Insurance announced the introduction of its Global Health Care product, which intends to offer health insurance coverage to all of its policyholders. According to a statement from the company, the product enables insured members to arrange any treatment without anxiety, whether it be in India or overseas, taking use of the world’s greatest medical facilities. The company added that Bajaj Allianz General Insurance and Allianz Partners worked together to give its clients a seamless claims experience through the company’s distinctive and large worldwide network of health care providers. One of the widest sum insured ranges offered on the Indian market is provided by the Global Health Care plan, which spans from Rs. 37.50 lakh to Rs. 3.75 crore (USD 1,00,000 to USD 10,00,000). The product comes with two plans, the “Imperial Plan” and the “Imperial Plus Plan,” both of which provide domestic and worldwide coverage. In-patient hospitalisation treatment, pre- and post-hospitalization costs with benefits like ambulance (air and road), living donor medical costs, modern treatment methods and technological advancement, mental illness treatment and rehabilitation, among other things, are covered by the domestic coverage for the “Imperial Plan” and “Imperial Plus Plan.” “The product addresses these exact reservations and provides you that relief in opting for best-in-class treatment anywhere in the world without worrying about the financial burden,” said Tapan Singhel, MD and CEO at Bajaj Allianz General Insurance. “Many of us want to look at international treatment options for our loved ones and ourselves, but we rarely opt for it because of the massive expenses anticipated, and it can potentially deplete the life savings of an individual. Indian residents of the country are offered the product, which has an individual sum insured available for a one-year policy cover period. The entry age ranges from 18 to 65 years for adult members and three months to 30 years for dependent children with a lifetime renewal option.

Bajaj Allianz launches product to provide global health insurance coverage Read More »

Cipla to invest Rs. 26 crores in GoApptiv, increasing its stake to 22%

Cipla, a pharmaceutical company, has agreed to pay approximately Rs 26 crore for an additional stake in digital technology firm GoApptiv Private, bringing its ownership to 22.02 percent, the company announced on Monday. According to Cipla, the investment will be made in equity shares and compulsorily convertible preference shares, and it will probably be finished within 30 days or on any other date that the parties may agree upon. Since investing in GoApptiv in June 2020, Cipla has seen growth and increased channel reach in lower-tier Indian towns. “This investment will further strengthen our partnership with GoApptiv enabling wider patient reach with affordable and quality drugs and end-to-end brand marketing and channel engagement across tier 2 – 6 towns in India. ‘Caring for Life’ is at the heart of what we do and will guide us towards making such strategic investments to help make a difference in the lives of our patients,” Cipla Limited’s MD and Global CEO, Umang Vohra, said. GoApptiv is a digital technology company that works with pharmaceutical companies to increase patient reach through digital solutions. For healthcare organisations, it provides end-to-end business solutions, including as distribution, digital solutions, integrated brand sales management, digital marketing, patient assistance, and healthcare data analytics. Source: PTI

Cipla to invest Rs. 26 crores in GoApptiv, increasing its stake to 22% Read More »